Immunovant, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2018 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Immunovant, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2018 to Q1 2024.
  • Immunovant, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending March 31, 2024 was $141M, a 53.8% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 $141M +$49.5M +53.8% Mar 31, 2024 10-K 2024-05-29
Q1 2023 $92M +$33.3M +56.7% Mar 31, 2023 10-K 2024-05-29
Q1 2022 $58.7M +$23.8M +68% Mar 31, 2022 10-K 2023-05-22
Q1 2021 $35M +$15.8M +82.7% Mar 31, 2021 10-K 2022-06-08
Q1 2020 $19.1M +$10.2M +115% Mar 31, 2020 10-K 2021-06-01
Q3 2019 $97K Sep 30, 2019 10-Q 2019-11-13
Q1 2019 $8.91M Mar 31, 2019 10-K 2020-06-29
Q4 2018 $0 Dec 31, 2018 10-Q 2019-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.